Results 71 to 80 of about 129,296 (209)

Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.

PLoS ONE, 2021
Background/objectivesPancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only marginally prolongs patient survival.
Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-Gispert, Leo Bühler, Bernhard Egger   +5 more
doaj   +1 more source

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul, D'Costa, Zenobia, Diana, Angela, Dushek, Omer, Fokas, Emmanouil, Jones, Keaton, Kruger, Philipp, Liu, Stanley, McKenna, W. Gillies, Muschel, Ruth J., Sansom, Owen J., Yin Lim, Su   +11 more
core   +1 more source

The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas

Tumor Biology, 2017
Pancreatic ductal adenocarcinoma is a highly malignant tumor with poor prognosis, and the biomarkers for the early diagnosis, targeting therapy, and prognosis are still not clinically available.
Xin Luo, Zhulin Yang, Xiao Liu, Ziru Liu, Xiongying Miao, Daiqiang Li, Qiong Zou, Yuan Yuan   +7 more
doaj   +1 more source

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer [PDF]

, 2017
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative ...
Andersen, Jesper B., Arricibita, Andrea, Bailey, Peter, Biankin, Andrew, Bozec, Aline, Chang, David K., Chuang, Chen-Hua, Guembe, Laura, Guruceaga, Elisabet, Gwinn, Dana, Khatri, Purvesh, Lecanda, Fernando, Martinez-Canarias, Susana, Mazur, Pawel K., Perurena, Naiara, Ponz-Sarvise, Mariano, Sage, Julien, Sayles, Leanne C., Sweet-Cordero, E. Alejandro, Valencia, Karmele, Vallejo, Adrian, Vicent, Silve, Zandueta, Carolina   +22 more
core   +3 more sources

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. [PDF]

, 2018
BACKGROUND:Although canonical Wnt signaling is known to promote tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), a cancer driven principally by mutant K-Ras, the detailed molecular mechanisms by which the Wnt effector β-catenin regulates such ...
Chen, Yibu, Genyk, Yuri S, Kahn, Michael, Lai, Keane KY, Lenz, Heinz-Josef, Lin, David P, Manegold, Philipp, Nguyen, Cu, Pandol, Stephen J, Teo, Jia-Ling, Wu, Kaijin, Wu, Yongfeng, Zhao, Yi   +12 more
core   +2 more sources

ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma [PDF]

, 2021
Farnaz Sedigheh Takhsha, Christel Vangestel, Muhammet Tanç, Sven De Bruycker, Maya Berg, Isabel Pintelon, Sigrid Stroobants, Guido R.Y. De Meyer, Pieter Van der Veken, Wim Martinet   +9 more
openalex   +1 more source

Emerging concepts in the management of pancreatic ductal adenocarcinoma

Laparoscopic, Endoscopic and Robotic Surgery, 2019
Pancreatic ductal adenocarcinoma is characterised by poor oncological outcomes with curative treatment only possible for a minority. Symptoms are dependent on the stage of the disease and location within the pancreas with constitutional decline often ...
Sanket Srinivasa, Rowan Parks
doaj   +1 more source

Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. [PDF]

, 2019
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with no efficacious treatment options. PDAC incidence is projected to increase, which may be caused at least partially by the obesity epidemic.
Eibl, Guido, Rozengurt, Enrique
core  

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma [PDF]

, 2017
Aims: CDX2 is widely used as a sensitive and specific immunomarker for colorectal carcinoma (CRC) but neither this sensitivity nor specificity is absolute. This study is the first known comparison of CDX1 and A33 against CDX2 as immunomarkers for CRC.
Adamczyk, Lukasz A., Cullen, Jayne, Evans, Shanna, Oien, Karin A., Oniscu, Anca, Wong, Newton A.C.S.   +5 more
core   +1 more source

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source